Christopher A. Kroeger sold $5.4M of MPLT
Chief Executive Officer at MapLight Therapeutics, Inc.. 147,639 shares at an average of $36.87, traded Jul 15, 2026, filed Jul 17, 2026.
Score components
- +25RoleCEO
- +25Trade size$5.4M at market
- +5Share of holdings soldSold 11% of holdings
- +15Cluster6 insiders selling within 14 days
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001658918-26-000014, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Jul 15, 2026 | SOpen-market sale Voting Common Stock | -18,950 | $36.00 | $682k | 1,375,144 | Jul 17, 2026 |
| Jul 15, 2026 | SOpen-market sale Voting Common Stock | -42,738 | $36.99 | $1.6M | 1,332,406 | Jul 17, 2026 |
| Jul 15, 2026 | SOpen-market sale Voting Common Stock | -90 | $37.54 | $3,379 | 1,332,316 | Jul 17, 2026 |
| Jul 16, 2026 | SOpen-market sale Voting Common Stock | -40,899 | $36.46 | $1.5M | 1,291,417 | Jul 17, 2026 |
| Jul 16, 2026 | SOpen-market sale Voting Common Stock | -28,091 | $37.26 | $1.0M | 1,263,326 | Jul 17, 2026 |
| Jul 16, 2026 | SOpen-market sale Voting Common Stock | -92 | $37.96 | $3,492 | 1,263,234 | Jul 17, 2026 |
| Jul 17, 2026 | SOpen-market sale Voting Common Stock | -16,779 | $37.90 | $636k | 1,246,455 | Jul 17, 2026 |
Related signals
Other insiders at MapLight Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 12Weak | MapLight Therapeutics, Inc. | Kristopher Hanson General Counsel | $193k 16,509 shares | -11% | |
| 51Moderate | MPLTbuy MapLight Therapeutics, Inc. | Catalyst4, Inc. owner | $50M 4,400,000 shares | +21% | |
| 9Weak | MapLight Therapeutics, Inc. | James Woodruff Lillie Chief Scientific Officer | $277k 22,082 shares | -10% | |
| 51Moderate | MapLight Therapeutics, Inc. | Catalyst4, Inc. owner | $15M 1,209,225 shares | +6% | |
| 50Moderate | MapLight Therapeutics, Inc. | Troy Cox director | $149k 15,620 shares | - | |
| 47Moderate | MapLight Therapeutics, Inc. | Jonathan Gillis CAO and Interim CFO | $1.4M 36,979 shares | -20% | |
| 40Moderate | MapLight Therapeutics, Inc. | Anatol Kreitzer Chief Discovery Officer | $1.3M 36,284 shares | -17% | |
| 40Moderate | MapLight Therapeutics, Inc. | Erin Pennock Foff Chief Medical Officer | $1.7M 47,158 shares | -14% | |
| 55Moderate | MapLight Therapeutics, Inc. | Kristopher Hanson General Counsel | $608k 16,508 shares | -10% | |
| 50Moderate | MapLight Therapeutics, Inc. | James Woodruff Lillie Chief Scientific Officer | $674k 18,267 shares | -8% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.